Human epididymis protein 4 reference limits and natural variation in a Nordic reference population

Tumor Biology

Volumn 33, Issue 1, 2012, Pages 141-148

  Bolstad, Nils ^a   Ijordsbakken, Miriam ^a   Nustad, Kjell ^a   Bjerner, Johan ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Furst Medical Laboratory   (Norway)

Author keywords

Epithelial cancer of the ovary; HE4; Human epididymis protein 4; Reference values

Indexed keywords

CREATININE; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REFERENCE VALUE; SEX DIFFERENCE; SMOKING HABIT;

EID: 83655197047     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0256-4     Document Type: Article

References (42)

1. JP Curtin 1994 Management of the adnexal mass Gynecol Oncol 55 S42 6 7835810 10.1006/gyno.1994.1340 1:STN:280:DyaK2M7jslGjsQ%3D%3D
2. R Sankaranarayanan J Ferlay 2006 Worldwide burden of gynaecological cancer: the size of the problem Best Pract Res Clin Obstet Gynaecol 20 207 25 16359925 10.1016/j.bpobgyn.2005.10.007 1:STN:280:DC%2BD287ltlSrtQ%3D%3D (Pubitemid 43380597)
3. CC Earle D Schrag BA Neville KR Yabroff M Topor A Fahey EL Trimble DC Bodurka RE Bristow M Carney JL Warren 2006 Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients J Natl Cancer Inst 98 172 80 16449677 10.1093/jnci/djj019 (Pubitemid 43205479)
4. MJ Engelen HE Kos PH Willemse JG Aalders EG de Vries M Schaapveld R Otter AG van der Zee 2006 Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma Cancer 106 589 98 16369985 10.1002/cncr.21616 (Pubitemid 43157622)
5. KC Giede K Kieser J Dodge B Rosen 2005 Who should operate on patients with ovarian cancer? An evidence-based review Gynecol Oncol 99 447 61 16126262 10.1016/j.ygyno.2005.07.008 (Pubitemid 41502860)
6. T Paulsen K Kjaerheim J Kaern S Tretli C Trope 2006 Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals Int J Gynecol Cancer 16 Suppl 1 11 7 16515561 10.1111/j.1525-1438.2006.00319.x
7. S Tingulstad FE Skjeldestad B Hagen 2003 The effect of centralization of primary surgery on survival in ovarian cancer patients Obstet Gynecol 102 499 505 12962932 10.1016/S0029-7844(03)00579-9 (Pubitemid 37311211)
8. RC Bast Jr M Feeney H Lazarus LM Nadler RB Colvin RC Knapp 1981 Reactivity of a monoclonal antibody with human ovarian carcinoma J Clin Invest 68 1331 7 7028788 10.1172/JCI110380 (Pubitemid 12235035)
9. RC Bast Jr TL Klug JE St E Jenison JM Niloff H Lazarus RS Berkowitz T Leavitt CT Griffiths L Parker VR Zurawski Jr RC Knapp 1983 A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 883 7 6310399 10.1056/NEJM198310133091503 (Pubitemid 13014028)
10. I Jacobs D Oram J Fairbanks J Turner C Frost JG Grudzinskas 1990 A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 922 9 2223684 10.1111/j.1471-0528.1990.tb02448.x 1:STN:280: DyaK3M%2FislKguw%3D%3D (Pubitemid 20340625)
11. S Tingulstad B Hagen FE Skjeldestad M Onsrud T Kiserud T Halvorsen K Nustad 1996 Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses Br J Obstet Gynaecol 103 826 31 8760716 10.1111/j.1471-0528.1996. tb09882.x 1:STN:280:DyaK28zjvFenug%3D%3D (Pubitemid 26291762)
12. KL Terry PM Sluss SJ Skates SC Mok B Ye AF Vitonis DW Cramer 2004 Blood and urine markers for ovarian cancer: a comprehensive review Dis Markers 20 53 70 15322314 1:CAS:528:DC%2BD2cXmslOmsbg%3D (Pubitemid 39149915)
13. KJ Carlson SJ Skates DE Singer 1994 Screening for ovarian cancer Ann Intern Med 121 124 32 8017726 1:STN:280:DyaK2c3ovVektQ%3D%3D (Pubitemid 24203497)
14. M Markman 1997 The role of CA-125 in the management of ovarian cancer Oncologist 2 6 9 10388024 1:CAS:528:DyaK1cXlvVCrs7g%3D (Pubitemid 27163434)
15. EP Diamandis 2010 Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102 1462 7 20705936 10.1093/jnci/djq306 1:CAS:528:DC%2BC3cXht1Oqtb7I
16. MT Galgano GM Hampton HF Frierson Jr 2006 Comprehensive analysis of HE4 expression in normal and malignant human tissues Mod Pathol 19 847 53 16607372 1:CAS:528:DC%2BD28Xkslels70%3D (Pubitemid 43780455)
17. I Hellstrom J Raycraft M Hayden-Ledbetter JA Ledbetter M Schummer M McIntosh C Drescher N Urban KE Hellstrom 2003 The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 3695 700 12839961 (Pubitemid 36793054)
18. KH Lu AP Patterson L Wang RT Marquez EN Atkinson KA Baggerly LR Ramoth DG Rosen J Liu I Hellstrom D Smith L Hartmann D Fishman A Berchuck R Schmandt R Whitaker DM Gershenson GB Mills RC Bast Jr 2004 Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis Clin Cancer Res 10 3291 300 15161682 10.1158/1078-0432.CCR- 03-0409 1:CAS:528:DC%2BD2cXkt1Ghs7o%3D (Pubitemid 38685433)
19. M Schummer WV Ng RE Bumgarner PS Nelson B Schummer DW Bednarski L Hassell RL Baldwin BY Karlan L Hood 1999 Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas Gene 238 375 85 10570965 10.1016/S0378-1119(99)00342-X 1:CAS:528:DyaK1MXnt1ylt74%3D (Pubitemid 29446174)
20. RG Moore AK Brown MC Miller S Skates WJ Allard T Verch M Steinhoff G Messerlian P DiSilvestro CO Granai RC Bast Jr 2008 The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 402 8 18061248 10.1016/j.ygyno.2007.10.017 1:CAS:528:DC%2BD1cXhtlOqtLo%3D (Pubitemid 351174295)
21. RG Moore DS McMeekin AK Brown P DiSilvestro MC Miller WJ Allard W Gajewski R Kurman RC Bast Jr SJ Skates 2009 A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 40 6 18851871 10.1016/j.ygyno.2008.08.031 1:CAS:528:DC%2BD1cXhsFajsL%2FJ
22. RG Moore M Jabre-Raughley AK Brown KM Robison MC Miller WJ Allard RJ Kurman RC Bast SJ Skates 2010 Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass Am J Obstet Gynecol 203 228.e1 6 10.1016/j.ajog.2010.03.043
23. F Jacob M Meier R Caduff D Goldstein T Pochechueva N Hacker D Fink V Heinzelmann-Schwarz 2011 No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting Gynecol Oncol 121 3 487 91 21420727 10.1016/j.ygyno.2011.02.022 1:CAS:528:DC%2BC3MXmtl2rsr0%3D
24. M Montagnana E Danese O Ruzzenente V Bresciani T Nuzzo M Gelati GL Salvagno M Franchi G Lippi GC Guidi 2011 The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 49 521 5 21288178 10.1515/CCLM.2011.075 1:CAS:528:DC%2BC3MXms1Wms74%3D
25. M Kamei S Yamashita K Tokuishi T Hashioto T Moroga S Suehiro K Ono M Miyawaki S Takeno S Yamamoto K Kawahara 2010 HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer Anticancer Res 30 4779 83 21115941 1:CAS:528:DC%2BC3MXhs1alug%3D%3D
26. RG Moore AK Brown MC Miller D Badgwell Z Lu WJ Allard CO Granai RC Bast Jr K Lu 2008 Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus Gynecol Oncol 110 196 201 18495222 10.1016/j.ygyno.2008.04.002 1:CAS:528:DC%2BD1cXoslWmsbc%3D
27. S Yamashita K Tokuishi T Hashimoto T Moroga M Kamei K Ono M Miyawaki S Takeno M Chujo S Yamamoto K Kawahara 2011 Prognostic significance of HE4 expression in pulmonary adenocarcinoma Tumour Biol 32 265 71 20953751 10.1007/s13277-010-0118-5 1:CAS:528:DC%2BC3MXitleitr0%3D
28. K Huhtinen P Suvitie J Hiissa J Junnila J Huvila H Kujari M Setala P Harkki J Jalkanen J Fraser J Makinen A Auranen M Poutanen A Perheentupa 2009 Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts Br J Cancer 100 1315 9 19337252 10.1038/sj.bjc.6605011 1:CAS:528:DC%2BD1MXksF2gs7c%3D
29. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2011. doi: 10.1002/ijc.26129.
30. P Rustad P Simonsson P Felding M Pedersen 2004 Nordic Reference Interval Project Bio-bank and Database (NOBIDA): a source for future estimation and retrospective evaluation of reference intervals Scand J Clin Lab Invest 64 431 8 15223705 10.1080/00365510410006694 1:CAS:528:DC%2BD2cXltFWlsLs%3D (Pubitemid 38918108)
31. R Development Core Team. R: A Language and Environment for Statistical Computing. [R 2.12.1]. 2011. Vienna, Austria, R Foundation for Statistical Computing, http://www.R-project.org. Ref Type: Computer Program. Accessed 25 Feb 2011.
32. J Bjerner 2007 Age-dependent biochemical quantities: an approach for calculating reference intervals Scand J Clin Lab Invest 67 707 22 17852817 10.1080/00365510701342070 1:CAS:528:DC%2BD2sXht1WgsLbF (Pubitemid 350041510)
33. HE Solberg 2004 The IFCC recommendation on estimation of reference intervals. The RefVal program Clin Chem Lab Med 42 710 4 15327004 10.1515/CCLM.2004.121 1:CAS:528:DC%2BD2cXmtlKgsL8%3D (Pubitemid 39137218)
34. P Rustad P Felding A Lahti PP Hyltoft 2004 Descriptive analytical data and consequences for calculation of common reference intervals in the Nordic Reference Interval Project 2000 Scand J Clin Lab Invest 64 343 70 15223700 10.1080/00365510410006306 1:STN:280:DC%2BD2czmvFCjtA%3D%3D (Pubitemid 38918104)
35. H Akaike 1974 A new look at statistical model identification IEEE Trans Autom Control 19 716 23 10.1109/TAC.1974.1100705
36. Tukey J. Exploratory data analysis. Reading: Addison-Wesley; 1977.
37. E Anastasi T Granato GG Marchei V Viggiani B Colaprisca S Comploj MG Reale L Frati C Midulla 2010 Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women Tumour Biol 31 411 5 20490961 10.1007/s13277-010-0049-1 1:CAS:528:DC%2BC3cXht1elt7bE
38. J Bjerner A Hogetveit AK Wold K Vangsnes E Paus T Bjoro OP Bormer K Nustad 2008 Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study Scand J Clin Lab Invest 68 703 13 18609108 10.1080/00365510802126836 1:CAS:528:DC%2BD1cXhsV2itbfO
39. RA Stockley J Shaw AG Whitfield TP Whitehead CA Clarke D Burnett 1986 Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions Thorax 41 17 24 3704962 10.1136/thx.41.1.17 1:STN:280:DyaL283gvVyrug%3D%3D (Pubitemid 16212827)
40. R Molina JM Escudero JM Auge X Filella L Foj A Torne J Lejarcegui J Pahisa 2011 HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases Tumour Biol 32 6 1087 95 21863264 10.1007/s13277-011-0204-3 1:CAS:528:DC%2BC3MXhtlagurnJ
41. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, Nagel D, Hofmann K, Krocker K, Burges A. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011 [Epub ahead of print].
42. Y Park JH Lee DJ Hong EY Lee HS Kim 2011 Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases Clin Biochem 44 10-11 884 8 21549107 10.1016/j.clinbiochem.2011.04.011 1:CAS:528:DC%2BC3MXnsVWnsr0%3D